Diabetic Med:与老年人相比,年纪稍小的2型糖尿病自我保健做法较差

2018-11-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项来自澳大利亚国家糖尿病审计的结果的研究。这项横断面研究比较了患有2型糖尿病年纪稍小的和老年人的自我护理实践。 数据来自澳大利亚国家糖尿病审计(ANDA),包括来自澳大利亚糖尿病中心的2552名患有2型糖尿病的成年患者。预先获得指定的人口统计学和临床变量。在≤64岁和> 64岁的人群中比较自我护理变量(身体活动,遵循饮食建议,药物

近日,国际杂志 《Diabetic Med》上在线发表一项来自澳大利亚国家糖尿病审计的结果的研究。这项横断面研究比较了患有2糖尿病年纪稍小的和老年人的自我护理实践。

数据来自澳大利亚国家糖尿病审计(ANDA),包括来自澳大利亚糖尿病中心的2552名患有2型糖尿病的成年患者。预先获得指定的人口统计学和临床变量。在≤64岁和> 64岁的人群中比较自我护理变量(身体活动,遵循饮食建议,药物依从性和血糖监测水平)。

参与者的平均年龄(± sd)总体为63±13岁,年小组为53±9岁,老年组为73±6岁。较大比例的年纪稍小的的HbA 1c水平> 53 mmol/ mol> 7.0%)(76vs68%),与老年人相比, 年纪稍小的的饮食建议(50vs32%)和遗忘药物(37vs22%)(所有P <0.001)执行情况较差。与年长者相比,年纪稍小的中较小比例的人按照推荐报告他们的血糖水平(60VS70%,P <0.001)。相似比例的年龄≤64岁和> 64岁的人需要胰岛素治疗(59vs57%,P = 0.200)。在校正性别,吸烟,胰岛素治疗,抑郁症和专职健康出勤率后,年纪稍小的与未遵循推荐的自我护理实践的几率增加2倍相关(所有P <0.001)。

尽管糖尿病病程较短,但年纪稍小的患者与2型糖尿病患者血糖控制较差和糖尿病患者自我护理较差有关。需要有针对性的策略来优化糖尿病自我护理实践,从而优化血糖控制。

原始出处:

N. Nanayakkara A. J. Pease S. Ranasinhaet al. Younger people with Type 2 diabetes have poorer selfcare practices compared with older people: results from the Australian National Diabetes Audit

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760868, encodeId=5c3f1e6086891, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 02 11:15:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970652, encodeId=d91d19e0652f7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Apr 17 03:15:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638828, encodeId=b095163882873, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 22 13:15:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609269, encodeId=774b16092693f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 02:15:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041997, encodeId=4564104199e04, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 14:15:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760868, encodeId=5c3f1e6086891, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 02 11:15:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970652, encodeId=d91d19e0652f7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Apr 17 03:15:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638828, encodeId=b095163882873, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 22 13:15:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609269, encodeId=774b16092693f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 02:15:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041997, encodeId=4564104199e04, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 14:15:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760868, encodeId=5c3f1e6086891, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 02 11:15:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970652, encodeId=d91d19e0652f7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Apr 17 03:15:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638828, encodeId=b095163882873, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 22 13:15:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609269, encodeId=774b16092693f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 02:15:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041997, encodeId=4564104199e04, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 14:15:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760868, encodeId=5c3f1e6086891, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 02 11:15:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970652, encodeId=d91d19e0652f7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Apr 17 03:15:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638828, encodeId=b095163882873, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 22 13:15:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609269, encodeId=774b16092693f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 02:15:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041997, encodeId=4564104199e04, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 14:15:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760868, encodeId=5c3f1e6086891, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Dec 02 11:15:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970652, encodeId=d91d19e0652f7, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Apr 17 03:15:00 CST 2019, time=2019-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638828, encodeId=b095163882873, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 22 13:15:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609269, encodeId=774b16092693f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 02:15:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041997, encodeId=4564104199e04, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 14:15:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Cell:揭示肠道菌群产生的咪唑丙酸导致2型糖尿病机制

近年来,肠道菌群(gut microbiota)与健康和几种疾病的病情有关。然而,仅少数研究探究了发生变化的肠道菌群是否能够直接影响疾病。

Diabetic Med:英国儿童和青少年2型糖尿病发病率持续上升?

近日,国际杂志 《Diabetic Med》上在线发表一项关于英国儿童和青少年2型糖尿病发病率持续上升的研究。为了估计17岁以下儿童的2型糖尿病发病率,将其与10年前的类似数据进行比较,并描述英国和爱尔兰共和国在诊断时的临床特征。 研究人员使用英国儿科监测小组报告框架,报告2015年4月1日至2016年4月30日期间每月<17岁儿童诊断出的2型糖尿病病例。 研究共报告106例,英

Diabetic Med:以情绪为中心的教育计划在减少成人2型糖尿病(VEMOFIT)患者困扰的有效性

近日,国际杂志 《Diabetic Med》上在线发表一项关于以情绪为中心的教育计划在减少成人2型糖尿病(VEMOFIT)患者困扰的有效性的群集随机对照试验的研究。研究通过比较一项简短的,基于价值观的情感为中心的教育计划(VEMOFIT)与另一个计划(积极倾听参与者的情绪体验,社会支持及其对健康诊所护理服务(注意力控制)评估马来成年2型糖尿病困扰有效性。 研究人员将患有严重糖尿病的马来成年人

Diabetic Med:2型糖尿病和智力残疾成人支持自我管理的随机对照可行性试验结果

近日,国际杂志 《Diabetic Med》上在线发表一项关于2型糖尿病和智力残疾成人支持自我管理的随机对照可行性试验研究。探讨在肥胖,2型糖尿病和智力残疾成年人群中进行支持性自我管理与常规治疗的可行性随机对照试验。 研究人员进行了一项单独的随机可行性试验。参与者是年龄> 18岁,患有轻度或中度智力残疾的成年人,生活在2型糖尿病社区,接受胰岛素以外的治疗。参与者具有同意研究和干预的心智

盘点:肠道菌群近期重要研究一览

肠道菌群是指在人体肠道中存在的种类繁多、数目惊人的微生物群体。普遍认为,肠道菌群参与炎症性肠病以及肥胖等代谢性疾病的发生。不良的肠道健康与肥胖、2型糖尿病、心脏病、炎症性肠病、结肠癌、神经疾病、孤独症和过敏症有关。   【1】肠道微生物及其介导的免疫应答对于开拓免疫治疗在结直肠癌中的应用 结直肠癌(Colorectal cancer, CRC)是大肠上皮黏膜在环境及

专家访谈:形象化的2型糖尿病管理原则

作为内分泌学家,我们知道良好的沟通对于2型糖尿病患者是多么重要。作为临床医生,我们都会培养一定的沟通技巧。我想与我的病人分享一些我用来鼓励他们更好地控制2型糖尿病的类比。